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Creatine kinase-1RNA interference (RNAi) is an essentialmethod inmolecular biology to reduce the expression of target genes and
thereby determine their function. Since this tool is known to also have unspeciﬁc effects, control experiments are
needed, chieﬂy among them the exclusion of off-target effects and the reconstitution of the genes' expression for
the rescue of the cellular RNAi effects.We show here that the knock-down of themitochondrial creatine kinase-1
(CKMT1) by RNA interference causes the dissipation of themitochondrialmembrane potentialΔΨm. Thiswas ac-
complishedwith 11 different RNAi constructs designed to target 7 distinct exons aswell as exon/intron junctions
making unspeciﬁc off-target effects unlikely. However, all our attempts failed to rescue human cells from ΔΨm
dissipation by the expression of CKMT1 alleles not targeted by RNAi. This included the transient and stable ex-
pression of the murine CKMT1 homologue, the expression of human codon usage-modiﬁed alleles, the transfec-
tion of a novel splice-isoform of CKMT1, and even the introduction of a human genomic clone for CKMT1 with
codon usage changes. Our results indicate that while off-target effects of RNA interference can easily be
addressed, the rescue of the knock-down phenotype is not necessarily achievable.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
RNA interference, the silencing of gene expression by double-
stranded RNA molecules, constitutes a key experimental tool in
molecular biology to elucidate the function of genes by selectively
ablating their expression [1]. Although RNAi constructs are designed
to be fully complementary to a single mRNA species, they may
inadvertently show complementary stretches to other non-target
mRNAs. The data on the required RNAi speciﬁcity vary, ranging
from reports that as little as 1–2mismatches within the 21–23 nucle-
otides used for RNAi disrupt degradation of the target mRNA [2–4] to
observations that as little as 11 bp of perfect homology can result in sig-
niﬁcant mRNA downregulation [5]. This can give rise to so-called off-
target effects. Additional effects can arise as transfected or expressed
RNAi constructsmay saturate the cell's RNAimachinery thus preventing
the processing of endogenous RNAi molecules (miRNA) which regulate
cell physiology [2]. There is also some evidence that the crosstalk of the
RNAi machinery and RNA editing pathways might have an effect on
RNAi-mediated gene silencing as they compete for common substrate
RNA [6]. Hence, despite the apparent ease of RNAi techniques, numer-
ous publications display RNAi data without sufﬁcient controls. Off-44 20 7594 7393.
ights reserved.target effects are frequently addressed by the use of scrambled
RNAi sequences and multiple RNAi target constructs. However,
often missing in publications using RNAi are phenotype rescue
experiments through the expression of an siRNA-resistant allele of
the targeted gene, which a number of researchers proclaimed as
the gold standard of RNAi [7–10].
Our experiments indicated that the knock-down of mitochondrial
creatine kinase-1 (CKMT1) leads to the collapse of the mitochondrial
membrane potentialΔΨm (Datler et al. unpublished). The octamer of
CKMT1 is a component of the permeability transition pore that gov-
erns the mitochondrial membrane potential [11]. We aimed at
setting up an RNAi phenotype rescue experiment in a human cellular
system in which endogenous CKMT1 would be downregulated by
siRNA or shRNA, while at the same time expressing an siRNA-
resistant CKMT1 construct in order to avoid DYm dissipation. This
was intended to, ﬁrstly, provide the ultimate proof for the observed
RNAi effect and, secondly, allow to determine which domains or
functions of the CKMT1 protein are vital for the cell. This would
answer important questions as to whether an enzymatically inactive
CKMT1 protein would rescue cells from ΔΨm collapse and apoptosis
induced by depletion of endogenous CKMT1 or whether CKMT1 mu-
tants incapable of forming the known octamers could replace endog-
enous CKMT1. Questions regarding the necessity of certain residues
or protein interaction domains of CKMT1 could also be addressed
using this experimental setup.
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can easily be addressed, rescuing cells from the cellular effects of RNAi
constructs can be difﬁcult.
2. Materials and methods
2.1. Cell culture and transfection
293T and HeLa cells were maintained in DMEM medium (Sigma,
UK) containing 10% FCS (Sigma, UK), 2 mM glutamine (Invitrogen,
UK), 100 μg/mL streptomycin, 100 U/mLpenicillin (Invitrogen), and so-
dium pyruvate (Invitrogen, UK). 293T and N2A cells were transfected
using X-fect (Clontech, UK), and HeLa cells were transfected with
Effectene (Qiagen) following the manufacturer's instructions. siRNA
transfections were performed using Effectene. Per 24 well plate 3.33 μl
of 20 mM siRNA (Invitrogen, UK) was mixed with 2 μl of Enhancer in
a total volume of 50 μl of EC buffer. Following 5 min incubation, 3 μl
of Effectene was added, and the mixture was vortexed for 10 s and
incubated for 15 min to allow for complex formation before adding
50 μl of serum- and antibiotic-free medium. After replacing the media
of the cellswith 225 μl of serum- and antibiotic-freemedia, the complex
mixture was added. 166 μl of 3× medium (30% FCS) was added after
4 h, and the medium was changed completely 8 h after transfection.
2.2. Reagents and antibodies
All genes were cloned into mammalian expression vectors with
cytomegalovirus (CMV) promoters and U6 promoter for the expression
of shRNA. The commercial expression vectors pcDNA3 (Invitrogen),
pIRESpuro2 (Clontech) and pIRES2-EGFP (Clontech) containing the
gene of interest were used for the transient and stable expression of
genes by plasmid transfection. pLenti7.3 (Invitrogen) was used for the
production of lentiviruses. pLKO.1 (Sigma-Aldrich) was used for the
production of lentiviruses or for the expression of shRNA constructs.
β-galactosidase or a scrambled shRNA construct was used as control
plasmid and a co-transfected GFP plasmid was used to determine the
transfection efﬁciency. Genomic constructs that contained codon usage
mutations mediating RNAi resistance were introduced and sequenced
by a company (GenScript, USA). Horseradish peroxidase-conjugated
(HRP) goat-anti-rabbit and mouse monoclonal anti-hexokinase II
were from Sigma-Aldrich (UK).
2.3. Production of stable cell lines after plasmid transfection
Cells were seeded in 6-well plates 24 h prior to transfection. 24 h
after the transfection with the IRES-PURO constructs, cells were se-
lected with 2 μg/ml puromycin. Clone pools were established or sin-
gle clones were picked after 100% of the control cells (no puromycin
resistance transfected) were dead. For IRES-EGFP constructs, cells
were selected in medium containing G418 at a concentration of
800 μg/ml. Colonies were analysed for GFP expression bymicroscopy
and positive colonies were picked with cloning rings. The ectopic ex-
pression of the gene of interest was veriﬁed using immunoﬂuorescent
and/or autoﬂuorescent FACS analysis and Western blot analysis. Stable
cell clones were maintained in 200 μg/ml G418.
2.4. Protein extraction and quantiﬁcation
Cell pellets were resuspended in 100 μl of RIPA buffer (150 mM
NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8.0) supplemented with complete protease inhibitor
cocktail (Thermo Fisher Scientiﬁc) and incubated on ice for 30 min.
The lysate was then centrifuged at 13,300 rpm for 30 min at 4 °C.
The supernatant containing the protein lysate was collected. Protein
concentrations were measured using either the Bradford protein
assay reagent (Bio-Rad) or BCA protein assay kit (Sigma-Aldrich).Protein lysates were diluted in 5× loading buffer (Thermo Fisher
Scientiﬁc) containing: 0.005% bromophenol blue as loading dye, 5%
β-mercaptoethanol (Sigma-Aldrich) as reducing agent, 10% SDS as
denaturing agent, 45% glycerol for loading, and 0.5 M Tris buffer.
Samples were then boiled at 100 °C for 10 min to ensure complete
denaturation of the proteins.2.5. Westen blotting
Total cell lysate was separated by SDS-PAGE in TGS-running buffer
(25 mM Tris–HCl, 192 mM Glycin, 0.1% w/v SDS). Proteins were
then transferred onto a PVDF membrane (Millipore, UK) by semidry
electroblotting (Biorad, UK), which were blocked with 5% BSA or
milk in PBS containing 0.1% Tween (PBS-T), incubated with primary
antibody, washed three times with PBS-T, and incubated with horse-
radish peroxidase-conjugated secondary antibody. Membranes were
developed by enhanced chemiluminescence with Immobilon ECL
reagent (Millipore, UK) onto photographic ﬁlms (Amersham, UK).
For multiple probing, membranes were incubated in Restore West-
ern Blot Stripping Buffer (Pierce, UK) for 15 min at 37 °C and washed
in PBS-T to completely remove primary and secondary antibodies.2.6. Reverse transcription PCR
RNA was isolated using 1 ml of Trizol (Invitrogen, UK) per well of
a 6 well plate and resuspended in 20 μl of ultrapure H2O. The Titan
One Tube RT-PCR kit (Roche, UK) was used to carry out RT-PCR
using 2 μg of total RNA. Speciﬁc primers for CKMT1 and βActin were
used for PCR reactions. 29 PCR cycles were used (10″ at 94 °C, 30″
at 54 °C and 50″ at 68 °C; followed by 7′ at 68 °C). PCR products
were separated by gel electrophoresis on a 1% agarose gel.2.7. DiOC6/PI co-staining
Supernatant and trypsinized cells were transferred to a FACS tube
and centrifuged for 5 min at 1500 rpm. The supernatant was discarded
and cells were resuspended in PBS. Mitochondria were loaded with
DiOC6 at a ﬁnal concentration of 50 nM for 30 min in a humidiﬁed incu-
bator (5% CO2, 37 °C) and for another 30 min at RT. PI was used as a cell
viability dye at a ﬁnal concentration of 5 mg/ml. Forward and side scat-
ters were used to characterise the cell population, and DiOC6 ﬂuores-
cence was acquired in Fl1 and PI ﬂuorescence in Fl2. FlowJo 7.25
(Stanford University, USA) was used for subsequent analysis.2.8. Immunostaining for FACS analysis
The supernatant and the adherent cells were harvested, centri-
fuged (1500 rpm, 5 min) and ﬁxed in 2% paraformaldehyde (Thermo
Scientiﬁc) in PBS for 20 min at 4 °C, then blocked in 10% FCS in PBS
for 30 min and permeabilized with 0.02% Triton X-100 for 30 min
at 37 °C. Cells were then centrifuged (1500 rpm, 5 min) and the pri-
mary antibody was diluted in 3% FCS in PBS, added and incubated for
1 h at 37 °C. Cells were then washed two timeswith 2 ml of 3% FCS in
PBS. For Alexa-labelled primary antibodies, cells were subsequently
analysed in the respective channel for ﬂuorescence intensity (Fl1 for
Alexa488). For staining using unlabelled primary antibodies, cells
were centrifuged, and the isotype-matched secondary antibody was
conjugated with Alexa488, diluted in PBS at a dilution of 1/500, added
to the tube and incubated for 1 h at 37 °C. Two washing steps with
2 ml of PBS were used to wash off unbound secondary antibody. The
cells were analysed by FACS using the Fl1 channel. FlowJo 7.25
(Stanford University, USA) was used for subsequent analysis.
2846 C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–28552.9. Antibodies
Primary antibodies (dilution 1:200 from stock) used are as follows:
anti-HA (HA.11 Clone 16B12 monoclonal antibody, Alexa488 labelled;
Catalogue number: A488-101L, Covance); anti-CKMT1 (rabbit polyclonal
CKMT1A Antibody 15346-1-A, Proteintech); CKMT1 (Proteinteich); anti-
HA (Sigma-Aldrich); and anti-GAPDH (Santa Cruz). Secondary antibody
(dilution 1:500 from stock) used was anti-rabbit IgG (H+L) from goat,
Alexa488 labelled.
2.10. Statistical analysis
Statistical analysis was performed using the unpaired student's
t-test. Data were obtained from n N 3 experiments for every ﬁgure and
were regarded as statistically signiﬁcant if p b 0.05 (*), 0.01 (**), and
0.001 (***) based on student's t-test.
3. Results
3.1. Transient expression of murine CKMT1 does not rescue cells from
mitochondrial depolarisation by human CKMT1 depletion
In order to design the rescue experiment, we used a highly homolo-
gous CKMT1 gene that deviates enough from the human CKMT1
sequence to be suitable for controlling the siRNA effects. The murine
CKMT1 protein shows greater than 98% identity at the amino acid se-




Fig. 1.MurineCKMT1 does not rescue human cells frommitochondrial depolarisation by CKMT1
site.Mismatches are indicated. (B) HeLa cellswere transfectedwith an siRNA targeted against th
post-siRNA transfection, cells were transfected with plasmids encoding HA-tagged murine CKM
E266 to L266mutation. Protein lysateswere obtained 72 h after siRNA transfection and assayed
were transfected with siRNA targeted against the coding sequence of human CKMT1 (siCK1(1
structs encodingmurine CKMT1 (mCKMT1-HA ormCKMT1mut-HA). Bgalwas used as a contro
membrane potential 72 h post-siRNA transfections. ns, non-signiﬁcant. (D)Western blot analy
was detected with a polyclonal CKMT1 primary antibody recognising human CKMT1 as well apair differences between human and murine CKMT1, we designed an
siRNA that targeted bp 413–431 of the human coding sequence of
CKMT1 but deviated from murine CKMT1 in two residues (Fig. 1A).
HeLa cellswere used to assesswhether the ectopic expression ofmurine
CKMT1 was affected by the simultaneous downregulation of endoge-
nous human CKMT1 with this siRNA duplex. As can be seen in Fig. 1B,
the expression of themurineHA-taggedmCKMT1 remained unchanged
by transfection of the siRNA, neither did an enzymatically inactive mu-
rine CKMT1 construct (mCKMT1mut) [12]. Thus, we expected these
murine CKMT1 expression constructs to rescue the phenotype of en-
dogenous CKMT1 depletion (mitochondrial depolarisation and subse-
quent cell death by apoptosis) (supplementary Figs. S1 and S2). HeLa
cells were transfectedwith the siRNA or a scrambled sequence and plas-
mids encoding the murine wild type mCKMT1 or mCKMT1mut were
transfected 16 h later. Previous experiments on the kinetics of protein
downregulation upon siCK1 plasmid transfections had shown that
there is no detectable CKMT1 depletion, nor ΔΨm dissipation within at
least the ﬁrst 24 h after siRNA transfection (not shown). In contrast to
our expectations neither overexpression of the murine CKMT1 wild
type nor CKMT1mut rescued cells from mitochondrial depolarisation
(Fig. 1C). The same experiment was also performed using different
transfection schedules: Neither co-transfection of siCK1 together with
murine CKMT1 nor reversing the transfection order with the plasmid
transfection ﬁrst changed the outcome (data not shown). Western
blot analysis of total CKMT1 expression revealed thatwhile endogenous
CKMT1 was depleted by siCK1 transfection, the murine CKMT1 con-
structs were expressed at even higher levels than endogenous humanknock-down. (A) Alignment of human andmurine CKMT1 at the chosen siCK1(1) binding
e coding sequence of human CKMT1 (siCK1(1)) or a scrambled control sequence (sc). 24 h
T1 (mCKMT1-HA) or the enzymatically inactive mutant mCKMT1mut-HA containing the
for expression of the respective constructs using amonoclonal HA antibody. (C) HeLa cells
)) or a scrambled sequence (sc). 16 h post-transfection, cells were transfected with con-
l. Stainingwith DiOC6 and subsequent FACS analysiswere used to assess themitochondrial
sis of protein lysates obtained from cells processed as described in (C). CKMT1 expression
s murine CKMT1.
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ments and throughout this study.3.2. Cells stably expressing murine CKMT1 still undergo mitochondrial
depolarisation upon depletion of endogenous human CKMT1
We hypothesised that the failure of the phenotype rescue upon
depletion of endogenous human CKMT1 and concomitant CKMT1 re-
constitution through expression of murine CKMT1 could be due to
the transient nature of the experiment. Consequently, HeLa cells sta-
bly expressing the murine CKMT1 constructs were obtained using
two different approaches: one used a bicistronic plasmid for murine
CKMT1 followed by an internal ribosome entry site (IRES) for a puro-
mycin resistance gene for antibiotic selection. The other approach
used a plasmid encoding a bicistronic mRNA formurine CKMT1 coupled
to EGFP for ﬂuorescent selection. Several individual clones were
obtained for each set of experiments and the expression of the respec-
tive murine construct at the correct size veriﬁed by Western blot anal-
ysis indicates that the murine constructs were expressed at a higher
level than endogenous CKMT1 (supplementary Fig. S3A). Additionally,
FACS analysis was employed to demonstrate the presence of the HA-
tagged constructs and EGFP in greater than 99% of all cells of the IRES-
PURO and IRES-EGFP clones, respectively (supplementary Fig. S3B, C).
Confocal microscopy conﬁrmed the mitochondrial-staining pattern of
the ectopically expressed murine CKMT1 constructs (supplementary
Fig. S3D). The HeLa cell clones stably expressing CKMT1 constructs
were then used for CKMT1 RNAi phenotype rescue experiments. As a
further control, we used two different siRNA sequences, both specif-
ically targeting human CKMT1 and comprising base pair mismatches
with murine CKMT1 (supplementary Fig. S4). Western blot analysis
revealed that the siRNAs could efﬁciently deplete cells of endoge-
nous as well as ectopically expressed human CKMT1 (Fig. 2A, B
clone). By contrast, the expression of the murine CKMT1 constructs
was not affected (Fig. 2C, D). Despite this, downregulation of endog-
enous human CKMT1 by the two siRNAs resulted in ΔΨm dissipation
in the IRES-EGFP and IRES-PURO clones stably expressing themurine
CKMT1 constructs (Fig. 2E and F). To rule out off-target effects, we
tested 3 additional target sequences for speciﬁc downregulation of
human CKMT1. A list of all RNAi sequences used to target human
CKMT1 and their alignments with murine CKMT1 is shown in sup-
plementary Fig. S5. Transfection of these RNAi constructs into theTable 1
RNAi constructs targeting CKMT1. All RNAi constructs used in this study are listedwith their nam
of human (h) ormurine (m) CKMT1. RNAi constructswere evaluated for the efﬁciency in CKMT1
Y, yes; N, no; n.a., not applicable.
Name Ofﬁcial identiﬁer Speciﬁcity Cds position (h/m
HUSH F15 FI576815 Homo sapiens/Mus musculus 212–240/215–24
shCK1 TRC703 TRCN0000243703 Homo sapiens/Mus musculus 333–353/336–35
shCK1 TRC058 TRCN000006058 Homo sapiens 373–393
siCK1(1) n.a. Homo sapiens 413–431
siCK1(2) n.a. Homo sapiens 426–444
HUSH F14 FI576814 Mus musculus 475–503
shCK1 TRC076 TRCN0000220076 Homo sapiens 602–622
HUSH F17 FI576817 Mus musculus 811–839
shCK1 TRC27 TRCN0000024927 Mus musculus 831–851
shCK1 TRC25 TRCN0000024925 Mus musculus 999–1019
shCK1 TRC704 TRCN0000243704 Homo sapiens 1158–1178
shCK1 TRC26 TRCN000024926 Homo sapiens/Mus musculus 168–188/171–19
shCK1 TRC28 TRCN0000024928 Mus musculus 376–396
shCK1 TRC608 TRCN0000180608 Homo sapiens 643–663
shCK1 TRC077 TRCN0000220077 Homo sapiens 731–751
shCK1 TRC700 TRCN0000243700 Homo sapiens 783–803
shCK1 TRC059 TRCN0000006059 Homo sapiens 1002–1022
shCK1 TRC24 TRCN0000024924 Mus musculus 1094–1114
HUSH F16 FI576816 Mus musculus 1084–1112IRES-PURO as well as IRES-EGFP clones resulted in mitochondrial
depolarisation irrespective of the expression of murine CKMT1
(Fig. 3).3.3. RNAi phenotype rescue experiments with codon usage-modiﬁed
human CKMT1
We speculated that subtle differences between human and
mouse CKMT1, despite being 98% identical, might be responsible
for the failure of murine CKMT1 to rescue human cells. Therefore,
we designed a human CKMT1 construct (hCKMT1(COD-HA)) altered
in codon usage by synonymous mutations by taking into account the
Homo sapiens codon usage frequencies accessible at the EBI server
(European Bioinformatics Institute, Cambridge, UK) (Fig. 4A). We also
generated an enzymatically inactive human CKMT1 harbouring these
codon usagemutations (hCKMT1(COD)mut-HA).Western blot analysis
conﬁrmed that these constructs were resistant to shRNA-mediated
depletion by transfection of the shCK1 TRC058 construct, whereas
wild-type CKMT1 expressionwas readily abrogated (Fig. 4B).We created
stable HeLa cell clones expressing theHA-tagged hCKMT1(COD) andHA-
tagged hCKMT1(COD)mut constructs together with clones ex-
pressing either Bgal or wild-type HA-tagged hCKMT1 as a control
(Fig. 4C). These clones were then transfected with shCK1 TRC076
(targeting all hCKMT1 constructs), shCK1 TRC058 (targeting endoge-
nous and ectopically expressed wild-type hCKMT1, but not the codon
usage-modiﬁed CKMT1), and a scrambled shRNA sequence. Transfec-
tion of both shCK1 constructs resulted in mitochondrial depolarisation
in all clones (Fig. 4D) despite the expression of hCKMT1(COD)-HA.
Western blot analysis conﬁrmed that the hCKMT1-HA construct could
efﬁciently be downregulated by both shCK1 constructs. By contrast,
the hCKMT1(COD)-HA construct was only downregulated by shCK1
TRC076, but shCK1 TRC058 transfection did not alter its expression
level (Fig. 4E). We have also observed ΔΨm dissipation in stable cells
that expressed very low levels ofWThCKMT1 and hCKMT1(COD) (sup-
plementary Fig. S6) and that high expression of this gene is anti-
apoptotic (supplementary Fig. S7), making it unlikely that the effect is
based on the high expression levels in the stable clones (Fig. 4C).
While the C-terminal HA-tag did not interfere with the octamer as-
sembly of CKMT1 as blue native gel electrophoresis conﬁrmed (data
not shown),we speculated that theHA-tag in hCKMT1(COD)-HA affect-
ed another physiological function of CKMT1 and hence was responsiblees, ofﬁcial identiﬁer, speciﬁcity, targeted sequence and exons of the coding sequence (cds)
protein knock-down (KD) and phenotype ofmitochondrial depolarisation (“mito depol”).
) Exon (1–9) Target sequence Kd Mito depol
3 2 TCTATGCACGGCTCTGCGACAAGACCACA Y Y
6 2–3 TGAGGAGACCTATGAGGTATT Y Y
3 GTGATCCAAGAGCGACACAAT Y Y
3 TGAAGCACACCACGGATCT Y Y
3 GGATCTAGATGCCAGTAAA Y Y
4 TATGTATTGTCTTCAAGAGTCAGAACTGG Y Y
4 ACCTGGCTGGACGTTACTATA Y Y
6 GTCATCTCTATGGAGAAAGGCGGCAACAT Y Y
6 CGGCAACATGAAGAGAGTGTT Y Y
7–8 GCCACTGCTGAGCAAAGATAA Y Y
9 CATCGATGGAGTAAACTATTT Y Y
1 2 CCGAAAGCACAACAACTGCAT N N
3 GTGATCCAAGAGCGGCATAAT N N
4 GCTGAACAGCAGCAGCTTATT N N
5 GGCCAGATGCTCGTGGAATTT N N
6 GGTGAATGAGGAGGATCATAC N N
7–8 GCTAAGCAAAGATAGCCGCTT N N
8 CGAGCGTCTTTGACATCTCTA N N




Fig. 2. Expression of murine CKMT1 does not rescue the phenotype of endogenous CKMT1 depletion. (A)–(D) Stable HeLa cell clones for hCKMT1-HA, mCKMT1-HA and
mCKMT1mut-HA (IRES-EGFP and IRES-PURO clones) were transfected with siRNAs targeting the coding sequence of human CKMT1 (siCK1(1) and siCK1(2)), or a scrambled
sequence (sc). 72 h post-transfection, protein lysates of the cells were assayed for the expression of total CKMT1 content using a polyclonal antibody recognising human and
murine CKMT1. (E) and (F) 72 h post-transfection the respective clones were analysed for mitochondrial depolarisation via DiOC6 staining and subsequent FACS analysis.
A
B
Fig. 3.Murine CKMT1 homologue fails to rescue the RNAi phenotype of CKMT1 depletion by 3 additional siRNAs. Stable HeLa cell clones for hCKMT1-HA, mCKMT1-HA andmCKMT1mut-
HAwere transfectedwithﬁveRNAi constructs targeting speciﬁcally the coding sequence of human CKMT1 (andnotmurine CKMT1) or a scrambled sequence (sc). 72 h (siRNA constructs)
and 96 h (shRNA constructs) post-transfection the IRES-EGFP clones (A) and IRES-PURO clones (B) were analysed for mitochondrial depolarisation via DiOC6 staining and subsequent
FACS analysis. ns, non signiﬁcant.
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2849C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–2855for the failure of the phenotype rescue. This seemed plausible since a
C-terminal domain has been described to mediate CKMT1 mem-
brane association with cardiolipin [13]. Therefore, we designed a
hCKMT1(COD) construct lacking the HA-tag, which thus was identi-
cal to the published human CKMT1 protein but still harboured the
codon usage mutation making it resistant to the RNAi-mediated de-
pletion by shCK1 TRC058. Stable IRES-PURO clones were established
for the constructs hCKMT1, hCKMT1(COD), and hCKMT1(COD)mut,
and a β-gal clone that served as an additional control. Both, HeLa
cells as well as 293T cells were used to cover possible cell-speciﬁc




Fig. 4. Expression of an HA-tagged synonymous human CKMT1 mutant does not res-
cue the phenotype of RNAi targeting endogenous CKMT1. (A) Introduction of 7 syn-
onymous mutations into the human CKMT1 coding sequence results in the codon
usage mutant hCKMT1(COD) whose translation yields an amino acid sequence iden-
tical to wild type human CKMT1. Numbers written above and below the base triplets
refer to their relative codon usage frequencies in human proteins according to data
available online at the European Bioinformatics Institute server. (B) HeLa cells were
transiently transfected with a shRNA construct targeting human CKMT1 (shCK1
TRC058) or a scrambled sequence (sc). 24 h post-transfection, constructs encoding
hCKMT1-HA, hCKMT1(COD)-HA and hCKMT1(COD)mut-HA were transfected. An-
other 24 h later, protein lysates were obtained and analysed by Western blotting
for total CKMT1 levels. (C) Validation of the expression of the HA-tagged hCKMT1
constructs in stable HeLa cell clones (IRES-PURO) by immunoﬂuorescence staining
for HA and subsequent FACS analysis. (D) Stable (IRES-PURO) HeLa cell clones were
transfected with shRNA constructs targeting endogenous hCKMT1. Both shCK1
TRC076 and shCK1 TRC758 also target ectopically expressed hCKMT1-HA. shCK1
TRC076 also targets ectopically expressed synonymous hCKMT1(COD)-HA mutant
of human CKMT1, while shCK1 TRC758 does not. 96 h post-transfection, cells were
analysed for mitochondrial depolarisation using DiOC6 staining and subsequent
FACS analysis. (E) Protein lysates from cells processed as in (D) were obtained and
probed for the presence of CKMT1 using a polyclonal CKMT1 antibody.iﬁed using immunoﬂuorescent staining in combination with FACS
analysis and Western blotting (supplementary Fig. S8). The stable
clones were infected with viral particles encoding shCK1 TRC076,
shCK1 TRC058, and a scrambled shRNA sequence. Both shCK1 con-
structs resulted in mitochondrial depolarisation in all HeLa and
293T clones (Fig. 5A, B). Western blot analysis conﬁrmed that the
hCKMT1 construct could efﬁciently be downregulated by both
shCK1 constructs, while the hCKMT1(COD) construct was only
downregulated by shCK1 TRC076 and shCK1 TRC058 did not change
its expression level (Fig. 5C).
3.4. Addressing off-target effects of RNAi experiments by using multiple
CKMT1 knock-down constructs
Taking into consideration our numerous CKMT1 RNAi phenotype
rescue attempts despite the presence of a protein identical to the
wild-type gene product, it seemed conceivable that the RNAi sequences
used exerted non-speciﬁc off-target effects that were independent of
CKMT1 downregulation. To address this, several additional RNAi
sequences were designed to target the CKMT1 mRNA and to correlate
the level of downregulation with the observed phenotype. In addition
to the 5 RNAi constructs used in the experiments above a total of 14 ad-
ditional RNAi sequences were tested for their capacity to downregulate
the CKMT1 protein and induce mitochondrial depolarisation. Table 1
lists all RNAi constructs, their respective target speciﬁcity, and the
mapping to the exons of the CKMT1 gene. 11 constructs were effec-
tive in downregulating CKMT1 expression on the protein level. Of
those, 4 constructs speciﬁcally downregulated murine CKMT1, 5
constructs targeted human CKMT1, and 2 constructs could be used
against both human and murine CKMT1 (supplementary Fig. S9A,
E). The remaining 8 RNAi constructs (3 targeting speciﬁcally murine
CKMT1, 4 targeting human CKMT1, and 1 construct against both
murine and human CKMT1), failed to downregulate CKMT1 protein
levels (supplementary Fig. S9B, F). All 11 constructs that efﬁciently
knocked-down CKMT1 resulted in highly signiﬁcant mitochondrial
depolarisation (supplementary Fig. S9C, G). By contrast, the 8 RNAi
constructs that did not knock-down CKMT1 on the protein level,
did also not exert any effect on mitochondrial polarisation (supple-
mentary Fig. S9D, H).
3.5. RNAi rescue experiments with a novel CKMT1 splice isoform
As our previous attempts to rescue the CKMT1 RNAi phenotype
failed, we hypothesised that cells express an alternative CKMT1 gene
product, which together with the published CKMT1 protein would be
downregulated by RNAi against CKMT1 and hence expression of the
published CKMT1 gene product alone would not rescue the phenotype.
AB
C
Fig. 5. Expression of a synonymous human CKMT1mutant does not rescue the RNAi phenotypewhen targeting the endogenous CKMT1. (A) Stable HeLa clones were infectedwith shRNA
constructs targeting endogenous hCKMT1. Both shCK1 TRC076 and shCK1 TRC758 target endogenous human CKMT1 as well as ectopically expressed hCKMT1. In addition, shCK1 TRC076
also targets the synonymous hCKMT1(COD) mutant of human CKMT1, while shCK1 TRC758 does not. 6 days post-infection with viral particles encoding the indicated RNAi constructs,
cells were analysed for mitochondrial depolarisation using DiOC6 staining and subsequent FACS analysis. (B) Same as in (A) for 293T cell clones. (C) Protein lysates from HeLa cells
processed as in (A) were obtained and probed for the presence of CKMT1 using a polyclonal CKMT1 antibody.
2850 C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–2855Therefore, we investigated the endogenous expression of the CKMT1
gene in more detail. Two copies of the CKMT1 gene are located in a du-
plicated genomic area (see supplementary Fig. S10A). We found that
CKMT1 was expressed from both loci (CKMT1A and CKMT1B) in HeLaand 293T cells as demonstrated by sequencing of the CKMT1 coding se-
quence ampliﬁed by a primer pair aligningwith the 5′ and 3′ ends of the
cds from CKMT1A/B, which revealed a consistent double peak at posi-
tion 1056 and position 1086 (supplementary Fig. S10B). These two
2851C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–2855differentmRNAs still encode identical proteins since they originate from
synonymous mutations. We then analysed all publicly available mRNA
sequences using the AceView database [14], which comprehensively
maps RNA transcripts to the genomic sequence. 615 cDNA clones
aligned to genomic CKMT1A and 654 cDNA clones to genomic
CKMT1B and were screened for matches to all CKMT1 RNAi con-
structs that resulted in mitochondrial depolarisation (Table 1). Five
transcripts (supplementary Fig. S11A, indicated by black arrow-
heads) for the CKMT1A gene and 3 transcripts of the CKMT1B gene
(supplementary Fig. S11B, indicated by black arrowheads) displayed
all functionally validated RNAi sites and thus were candidates for al-
ternative vital gene products. These transcripts either encode the
published CKMT1 protein with different UTRs or with a 5′-extended
exon 2 associated with different UTRs (supplementary Fig. S11A
transcripts a, b and c, supplementary Fig. S11B transcript a). These
would encode for a 93 bp longer exon 2 on the mRNA level and
thus contribute to a 31aa longer protein upon translation. In order
to examine the existence of this alternatively spliced CKMT1 variant
in our cellular system we set up a PCR experiment with a forward
primer hybridising to a sequence at the ATG start codon and 2 different
reverse primers, one corresponding to the binding sequence of RNAi
construct siCK1(1) in exon 3, and a second reverse primer correspond-
ing to the beginning of the published exon 2. Both primer sets resulted
in two clearly distinguishable PCR bands, one corresponding to the
expected published CKMT1 transcript (Fig. 6A, white arrow) and an
unknown, approximately 100 bp longer second band (red arrow).
Sequencing conﬁrmed the existence of 2 different transcripts, which
aligned to the human CKMT1 genes (Fig. 6B). The longer CKMT1 tran-
script corresponds to a 5′-extended alternatively spliced exon 2,
which can be aligned to both CKMT1A and CKMT1B. Transcripts differ-
ing by exactly this alternatively spliced exon 2 were also found when
amplifying CKMT1 mRNA transcripts with primer sets aligning to the
start and published stop codon of the published CKMT1mRNA (supple-
mentary Fig. S12A). A Clustal Omega sequence alignment of the
sequenced PCR products is shown in supplementary Fig. S12B. Using
BLAST search we could align the novel CKMT1 transcript with several
human cDNA clones and other predicted mRNAs including from
mouse, with the extended exon 2 being present across mRNAs and
sequenced genomes of the mammalian kingdom (BLAST results not
shown). When searching the non-redundant human protein sequence
database available at the NCBI, we found that the novel CKMT1 mRNA
transcript fully aligns to the “unnamed protein product [Homo sapiens],
accession BAH14495”.
We set out to analyse whether additional CKMT1 isoforms could
exist on the protein level and isolated a genomic DNA fragment
from HeLa cells using primers spanning the whole CKMT1 gene
(including a 1151 bp upstream region of the published start ATG
codon to include the whole promoter and a 131 downstream region
from the published TAA stop codon including the predicted
polyadenylation site; primers were amplifying CKMT1A or CKMT1B
sequences). The resulting 6.3 kb fragment (Fig. 6C) was subcloned
into the pcDNA3.1 expression vector and clones were analysed for
their capacity to express CKMT1 gene products by plasmid transfec-
tion. The clone with the highest CKMT1 expression level as deter-
mined by Western blot analysis using a polyclonal CKMT1 antibody
was selected for further studies (Fig. 6D). Full length sequencing re-
vealed that the genomic locus ampliﬁed corresponds to the human
published CKMT1A locus with 6288 out of 6322 base pairs identical
to “Homo sapiens chromosome 15 genomic scaffold, alternate assem-
bly CHM1_1.0 Sequence ID: ref NW_004078084.1”. Supporting evi-
dence for the above described novel CKMT1 splice isoform came
from SDS-PAGE and Western blots using a polyclonal CKMT1 anti-
body, which detected endogenous CKMT1 as 2 distinct bands
(Fig. 6E, ﬁrst right hand panel). Based on the molecular weight, the
second, upshifted band (blue arrowhead) could correspond to the
31aa extended CKMT1 isoform. Plasmid transfection of CKMT1(iso)resulted in 3 distinct bands (Fig. 6E, red arrows), with the lowest
one running at the same size as the upshifted endogenous CKMT1
band (blue arrows). Overexpression of the genomic CKMT1 locus
by plasmid transfection of CKMT1(GEN) yielded 2 distinct bands
(Fig. 6F, last panel) identical in appearance to endogenous CKMT1.
Based on our evidence for the expression of the alternatively spliced
CKMT1 isoform we speculated that this isoform could rescue the RNAi
phenotype. Therefore, we constructed the CKMT1(iso)COD allele resis-
tant to RNAi by shCK1 TRC058 (Fig. 7A) and set up a transient rescue ex-
periment. HeLa cells were transfected with plasmids encoding shCK1
TRC058 or a scrambled control sequence and 24 h later transfected
with CKMT1(iso)COD, CKMT1(iso)COD plus CKMT1(COD), or hCKMT1
as a control. Analysis 5 days after transfection revealed an equal loss
of the mitochondrial membrane potential in the cells (Fig. 7B) regard-
less of the transfected CKMT1 construct. Other transfection schedules
including simultaneous co-transfections of the RNAi and the CKMT1 ex-
pression constructs andmultiple transfections for the CKMT1 constructs
yielded similar results (data not shown). Mitochondrial depolarisation
was induced although CKMT1(iso)COD expression levels as well as
combined CKMT1(iso)COD and hCKMT1(COD) expression levels were
above the endogenous CKMT1 expression level (in N76% or N80% of
cells, respectively) (Fig. 7C and D).
3.6. RNAi rescue experiments with the genomic CKMT1 clone
In an attempt to perform an RNAi rescue experiment that would
take into account potential additional alternative gene products as
well as genomic rearrangements in the cell line used, we ampliﬁed
the CKMT1 genomic loci from HeLa cells. To use the expression vector
of the CKMT1 genomic locus as the ultimate approach for rescuing the
CKMT1 RNAi phenotype we designed codon usage mutations for
shCK1 TRC058 as well as shCK1 TRC076 (Fig. 8A, B). These mutations
were introduced commercially and fully sequence-veriﬁed. The expres-
sion and RNAi resistance of the resulting constructs, CKMT1(GEN)
COD(058) and CKMT1(GEN)COD(076) were veriﬁed using Western
blot analysis. As expected, the parent plasmid CKMT1(GEN) could be
downregulated by the RNAi constructs shCK1 TRC058 and shCK1
TRC076, whereas the CKMT1(GEN)COD(058) construct was resistant
to RNAi by TRC058 but still susceptible to downregulation by shCK1
TRC076. Conversely, the CKMT1(GEN)COD(076) construct was resis-
tant to RNAi by the shCK1 TRC076 construct but was downregulated
by the shCK1 TRC058 construct (Fig. 8C). A time-course experiment
revealed that the CKMT1(GEN) plasmid was expressed at higher
levels than endogenous CKMT1 for at least 6 days post-transfection
(Fig. 8D). The RNAi resistant CKMT1(GEN) constructs were subse-
quently introduced by transfection. As can be seen in Fig. 8E, tran-
sient overexpression of the RNAi-resistant genomic constructs and
their respective RNAi construct, resulted in a pronounced increase
in CKMT1 levels. CKMT1(GEN)COD(058) or CKMT1(GEN)COD(076)
transfection into cells expressing shCK1 TRC058 or shCK1 TRC076
resulted in an elevated CKMT1 expression level in N 61% or N 54% of
cells, respectively, compared to endogenous CKMT1 in cells infected
with an RNAi construct encoding a scrambled shRNA sequence. Mi-
tochondrial depolarisation was detectable in all cells infected with
RNAi constructs targeting CKMT1 (Fig. 8F) irrespective of the pres-
ence of absence of genomic CKMT1 plasmids.
4. Discussion
The apparent simplicity of the RNAi technique led it to be one of
themost popular methods in molecular biology; however, numerous
publications display RNAi data without sufﬁcient controls [7] ad-
dressing in particular (i) off-target effects and (ii) phenotype rescue
experiments. To address off-target effects and increase conﬁdence in
data relating to an RNAi effect the use of several independent RNAi








Fig. 6. Experimental veriﬁcation of an alternatively spliced full length CKMT1 mRNA and cloning of the 6.3 kb genomic CKMT1 locus. (A) cDNA from HeLa cells was used for amplifying
CKMT1 transcripts using primers aligning to the start codon area (ATG) and to the siCK1(1) hybridization site in exon 3 or the start of exon 2. The PCR product was separated on a 2%
agarose gel. The white arrow indicates the predicted band for the published CKMT1 transcript, and the red arrow indicates an approximately 100 bp longer unknown PCR product.
(B) Sequencing ﬁle for the PCR products shown in (A). cDNA from HeLa and 293T cells was used for amplifying CKMT1 transcripts using primers aligning to the sequence comprising
the start and stop codon. PCR products were separated on an agarose gel and individual bands were sequenced. The alignment of the two different PCR products with the published
CKMT1mRNA is shown in a dot matrix view. (C) Genomic DNAwas isolated from HeLa cells and the 6.3 kb CKMT1 locus (including promoter and polyadenylation signal) was ampliﬁed
by PCR and resolved on a 0.8% agarose gel. (D) AWestern blot of HeLa cells transfectedwith the genomic CKMT1 locus subcloned into an expression vector is shown. A polyclonal CKMT1
antibody was used to visualise overexpressed and endogenous CKMT1. (E) SDS-PAGE and Western blot of endogenous CKMT1, overexpressed CKMT1(iso) and overexpressed CKMT1
from a genomic clone CKMT1(GEN). Black arrows indicate the known endogenous CKMT1, blue arrows indicate bands running at the same size as the upshifted endogenous CKMT1
band; and red arrows indicate the 3 distinct bands observed after overexpression of CKMT1(iso).
2852 C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–2855RNAi constructs should result in comparable gene silencing and thus
similar phenotypes. However, the rescue of the RNAi effect by the ex-
pression of an siRNA-resistant allele of the targeted gene has been
suggested as the “ultimate” control for RNAi data [7–10]. In our
study we used 7 distinct RNAi constructs in human cells and 4 dis-
tinct RNAi constructs inmurine cells (11 constructs in total) to efﬁcient-
ly downregulate the CKMT1 protein expression (Table 1). Given that
those 11 independent RNAi constructs resulted in mitochondrial
depolarisation and that 8 constructs that were complementary to the
CKMT1 mRNA target sequence but failed to cause gene silencing did
also not induce mitochondrial depolarisation, it is highly unlikely thatthe observed cellular consequence is an off-target effect of RNAi. How-
ever, we failed to accomplish the second test for RNAi effects: to rescue
the phenotype (mitochondrial depolarisation) when we expressed al-
leles of CKMT1 that could not be targeted by the RNAi molecules.
There are a number of possible explanations for this.
Firstly, for the CKMT1 rescue alleles we used synonymous muta-
tions. Recent discoveries have establishing that synonymous muta-
tions can have functional consequences [15]. These can arise from
various mechanisms: Synonymous point mutations, especially at
exon/intron junctions, can lead to aberrant mRNA splicing which
can even be associated with diseases [16]. Synonymous mutations
Fig. 7. The novel splice isoform CKMT1(iso) does not rescue the RNAi CKMT1 phenotype in a transient experiment. (A) HeLa cells were transfected with RNAi plasmids encoding shCK1
TRC058 or a scrambled sequence. 24 h post-transfection, cells were transfected with expression constructs for the novel splice isoform CKMT1(iso) or RNAi-resistant CKMT1(iso)COD.
Another 24 h later protein lysates were harvested and assayed for CKMT1 expression using Western blotting with a polyclonal CKMT1 antibody. (B) HeLa cells were transfected as in
(A) and assayed for mitochondrial depolarisation 5 days post the initial transfection by DiOC6 staining and subsequent FACS analysis; ns non-signiﬁcant. (C) FACS analysis for CKMT1 ex-
pression in cells processed as in (A) 5 days post the initial transfection. (D) Western blot analysis for CKMT1 expression in cells treated as in (A) 4 days post the initial transfection.
2853C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–2855can also affect mRNA stability as well as accessibility to regulation by
endogenous miRNAs [17] and thus protein expression levels [18].
Additionally, the mRNA structure/foldingmight change upon the intro-
duction of synonymousmutations impacting on the ribosomal access tostart protein translation as well as the speed of translation [19]. The lat-
ter not only affects protein levels, but can also impact on the conforma-
tion of the protein via a mechanism called co-translational folding [20].






Fig. 8. Expression of the RNAi-resistant genomic clone CKMT1(GEN) COD does not rescue the RNAi CKMT1 phenotype. (A, B) Alignment of the genomic CKMT1 sequence with the syn-
onymous codon usage mutations introduced to achieve RNAi resistance. CKMT1(GEN)COD(058) is resistant to shCK1 TRC058 due to 7 introduced mismatches (highlighted by arrows);
CKMT1(GEN)COD(076) is resistant to shCK1 TRC076 due to 5 introduced mismatches (highlighted by arrows). Numbers above and below the base triplets refer to their relative codon
usage frequencies in human proteins according to data available online at the European Bioinformatics Institute server. (C) HeLa cells were transfected with shCK1 TRC058, shCK1
TRC076 or a scrambled RNAi construct. 24 h post-transfection, CKMT1(GEN), CKMT1(GEN)COD(058) or CKMT1(GEN)COD(076) was introduced. Another 24 h later, protein lysates
were assayed for the expression of CKMT1 byWestern blotting using a polyclonal CKMT1 antibody. (D) HeLa cells were transfectedwith CKMT1(GEN) or Bgal as a control and the expres-
sion of CKMT1wasmonitored over the following 6 days byWestern blotting using a polyclonal CKMT1 antibody. (E) HeLa cells were infectedwith viral RNAi particles encoding for shCK1
TRC058, shCK1 TRC076, or a scrambled sequence. 24 and 72 h post-infection, cells were transfected with CKMT1(GEN), CKMT1(GEN)COD(058), CKMT1(GEN)COD(076) or Bgal as a con-
trol. 6 days after the initial infection, CKMT1 expressionwas quantiﬁedby immunoﬂuorescent CKMT1 staining and subsequent FACS analysis. (F) Cells processed as in (E)were assayed for
mitochondrial depolarisation by DiOC6 staining and FACS analysis. ns, non-signiﬁcant.
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2855C. Datler, S. Grimm / Biochimica et Biophysica Acta 1833 (2013) 2844–2855open reading frame could therefore inadvertently have affected the
structure/function of the CKMT1 protein(s), as the modiﬁed base trip-
lets display distinct relative codon usage frequencies in human proteins.
However, codon usage modiﬁed ectopically expressed CKMT1 can still
form octamers (data not shown), which is the only tertiary structure
described for CKMT1. In addition, we used two human codon mutants
(076 and 058) making structure/function problems rather unlikely.
Secondly, genomic RNAi rescue experiments were conducted using
the CKMT1A genomic locus. As the CKMT1 mRNA is expressed from
both genomic loci CKMT1A and CKMT1B, it is conceivable that only
one genomic locus encodes the CKMT1 gene product that is vital for
cell viability (all RNAi constructs used in this study target CKMT1A
and CKMT1B). Considering the new paradigm that the codon usage on
the mRNA level can determine protein function, it is theoretically con-
ceivable that the two synonymous point mutations distinguishing
CKMT1A and CKMT1B are mediating distinct protein functions.
A third possible explanation is that all RNAi rescue experiments
used transient or stable overexpression of RNAi-resistant CKMT1
constructs, which led to higher CKMT1 level than the endogenous
CKMT1. However, one could argue that this cannot explain the failure
of the rescue experiments since transient CKMT1 overexpression
mediates apoptosis inhibition and protects against mitochondrial
depolarisation [21].
Another explanation for the failed RNAi rescue could be the hypoth-
esis that CKMT1 protein levels serve as a ﬁnely tuned sensor for
detecting a relative decrease in total CKMT1 protein that would trigger
apoptosis induction. However, as can be seen in Fig. 8D, overexpression
induced by transfection of the genomic CKMT1 construct led to a sub-
stantial increase of CKMT1 levels, which decayed over the next 5 days.
Despite the drop of total CKMT1 levels, cells did not induce mitochon-
drial depolarisation (data not shown).
Lastly, we cannot formally exclude that the CKMT1 locus encodes an
as yet fully un-described gene product that is affected by all the RNAi
constructs used and is vital for cell survival such as an additional alter-
natively spliced mRNA transcript or microRNA encoded in the CKMT1
intron sequences.
With the ever-increasing popularity of RNAi experiments it is im-
portant to perform the relevant controls. Off target effects can rela-
tively easily be addressed by using a number of RNAi molecules
targeting different sequences in the gene to be downregulated. However,
the rescue experiment, the reduction of the cellular effect induced by the
downregulation of the target gene, is more challenging and according to
our data on CKMT1 can be very difﬁcult, if not impossible, to accomplish.
Hence, our data establish a precedent for other cases in which the RNAi
rescue is not feasible.4.1. Conclusion
RNAi is one of the most widely used tool in molecular biology but is
speciﬁcity has to be controlled.Weobserved the dissipation of themito-
chondrialmembrane potential whenwe targetedmitochondrial creatine
kinase-1 (CKMT1) by various RNAi constructs. However, we were not
able to rescue this phenotype by the expression of CKMT1 alleles not
targeted by RNAi. This included the expression of murine CKMT1, of
human codon usage-modiﬁed alleles, of a novel splice-isoform of
CKMT1, and even the introduction of a genomic clone for CKMT1 with
codon usage changes. With this study we set a precedent that not all
controls for RNAi experiments can be accomplished.Abbreviations
CKMT1 mitochondrial creatine kinase-1
RNAi RNA interference
miRNA microRNA
SDS-PAGE sodium dodecyl sulfate-ployacrylamide gel electrophoresis
FACS ﬂuorescence activated cell sorter
CMV cytomegalovirus
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